Skip to contentpdufa.bio

AP03 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

AP03 Phase is an Avalyn Pharma Inc. program in healthy volunteers (pulmonary fibrosis program). Its next catalyst is a Readout in Q4 2027.

AVLN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: healthy volunteers (pulmonary fibrosis program). Sponsor: Avalyn Pharma Inc. (AVLN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027AVLN

Specialist biotech funds holding AVLN, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors350,000$10.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is AP03 Phase's next FDA decision or readout?

The next tracked catalyst for AP03 Phase is a Readout in Q4 2027.

What happened at AP03 Phase's most recent FDA decision?

No FDA decision for AP03 Phase is in our archive yet.

What is AP03 Phase used for?

In our records AP03 Phase is under review or in development for healthy volunteers (pulmonary fibrosis program).

Who makes AP03 Phase?

Avalyn Pharma Inc. (AVLN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.